Pulmonary Tuberculosis With TB Meningitis CME

Daniel M. Musher, MD; Physician Reviewer: Nasia Safdar, MD, MS; Educational Design Consultant: Anthony H. Choi, PhD Author Information and Disclosures

Release Date: December 28, 2007; Valid for credit through December 28, 2008

Credits Available
Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians

To participate in this activity: 1) review the target audience, learning objectives and author disclosures, 2) study the education content 3) answer the posttest and evaluation 4) view/print certificate View details

Contents of This CME Activity

Related Link
For easy access to comprehensive resources for antimicrobial resistance visit: www.AREAinitiatives.org

Legal Disclaimer

The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Copyright © 2007 The University of Wisconsin Board of Regents and CME Enterprise.
Wyeth
Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Discuss efficacy and side effect profiles of antibiotics that have been recently approved or are in phase III clinical trials
  2. Describe how the problem of hospital antimicrobial resistance impacts their clinical practice environments
  3. Based on clinical guidelines, likely pathogens, and the patient's specific medical history and clinical presentation, implement initial management strategies for patients with, or at risk for, bacterial infections
  4. Use culture data to determine ongoing management for a patient with a bacterial infection
  5. Obtain cultures in order to conduct antimicrobial susceptibility testing and use that data to determine definitive therapy for a patient with a bacterial infection
  6. Evaluate the appropriate use of the local antibiogram for their institutions to determine empiric therapy for their patients with bacterial infections
Authors and Disclosures

Daniel M. Musher, MD
Disclosure: Daniel M. Musher, MD, has no relevant relationships to disclose in regard to this activity.


Nasia Safdar, MD, MS
Disclosure: Nasia Safdar, MD, MS, has no relevant relationships to disclose in regard to this activity.


Anthony H. Choi, PhD
Disclosure: Anthony H. Choi, PhD, has no relevant relationships to disclose in regard to this activity.
 
The University of Wisconsin School of Medicine and Public Health
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Wisconsin School of Medicine and Public Health and CME Enterprise. The University of Wisconsin School of Medicine and Public Health is accredited by the ACCME to provide continuing medical education for physicians.

The University of Wisconsin School of Medicine and Public Health designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.